Merrimack Pharmaceuticals Company Profile (NASDAQ:MACK)

About Merrimack Pharmaceuticals

Merrimack Pharmaceuticals logoMerrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. Its ONIVYDE (irinotecan liposome injection), also known as MM-398, is an encapsulation of the marketed chemotherapy drug irinotecan in a liposomal formulation. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. MM-121 is a fully human monoclonal antibody that targets Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3). MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes. MM-151 is an oligoclonal therapeutic designed to bind to non-overlapping epitopes of EGFR (ErbB1).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MACK
  • CUSIP: 59032810
Key Metrics:
  • Previous Close: $4.77
  • 50 Day Moving Average: $5.40
  • 200 Day Moving Average: $6.47
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.42
  • P/E Growth: -0.94
  • Market Cap: $616.47M
  • Outstanding Shares: 129,240,000
  • Beta: 1.99
Additional Links:
Companies Related to Merrimack Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Merrimack Pharmaceuticals (NASDAQ:MACK) (?)
Ratings Breakdown: 3 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $11.20 (134.80% upside)

Analysts' Ratings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateFirmActionRatingPrice TargetDetails
8/19/2016BTIG ResearchInitiated CoverageNeutralView Rating Details
8/10/2016Robert W. BairdReiterated RatingNeutral$8.00 -> $7.00View Rating Details
8/5/2016JPMorgan Chase & Co.Lower Price TargetOverweight$9.00 -> $8.00View Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$16.00 -> $13.00View Rating Details
8/5/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details
5/20/2016MizuhoReiterated RatingBuy$13.00View Rating Details
12/30/2015Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details
8/11/2015Cantor FitzgeraldReiterated RatingBuy$16.00View Rating Details
5/13/2015GuggenheimInitiated CoverageBuy$15.00View Rating Details
(Data available from 8/26/2014 forward)


Earnings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.33)($0.40)$33.35 million$33.70 millionViewN/AView Earnings Details
5/2/2016Q116($0.38)($0.33)$24.16 million$21.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.41)($0.41)$31.73 million$21.42 millionViewListenView Earnings Details
11/9/2015Q315($0.40)($0.38)$14.04 million$16.44 millionViewN/AView Earnings Details
8/10/2015Q215($0.31)($0.21)$17.57 million$36.60 millionViewListenView Earnings Details
5/7/2015($0.30)($0.32)ViewN/AView Earnings Details
2/26/2015Q4($0.23)($0.09)ViewN/AView Earnings Details
11/10/2014($0.12)($0.27)ViewN/AView Earnings Details
8/11/2014($0.32)($0.17)ViewN/AView Earnings Details
5/1/2014Q114($0.30)($0.27)$11.93 million$13.03 millionViewN/AView Earnings Details
2/27/2014($0.29)($0.33)ViewN/AView Earnings Details
11/7/2013($0.34)($0.39)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.28)($0.31)$13.68 million$18.45 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.26)($1.76)$11.77 million$12.58 millionViewN/AView Earnings Details
11/14/2012Q312($1.81)$8.60 million$11.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Merrimack Pharmaceuticals (NASDAQ:MACK)
Current Year EPS Consensus Estimate: $-0.91 EPS
Next Year EPS Consensus Estimate: $-0.88 EPS


Dividend History for Merrimack Pharmaceuticals (NASDAQ:MACK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/25/2016Birgit M SchoeberlInsiderSell50,000$5.50$275,000.00View SEC Filing  
3/17/2016Michael E PorterDirectorBuy5,000$7.20$36,000.00View SEC Filing  
3/15/2016Michael E PorterDirectorBuy5,000$7.65$38,250.00View SEC Filing  
3/8/2016Michael E PorterDirectorBuy10,000$7.09$70,900.00View SEC Filing  
3/3/2016Michael E PorterDirectorBuy15,000$6.39$95,850.00View SEC Filing  
3/1/2016Michael E PorterDirectorBuy20,000$6.11$122,200.00View SEC Filing  
2/29/2016Vivian S LeeDirectorBuy35,000$5.50$192,500.00View SEC Filing  
2/29/2016William M McclementsInsiderBuy2,000$5.72$11,440.00View SEC Filing  
1/5/2016Edward J. StewartinsiderSell4,000$8.00$32,000.00View SEC Filing  
12/1/2015Edward J. StewartinsiderSell5,000$9.33$46,650.00View SEC Filing  
11/2/2015Edward J. StewartinsiderSell6,000$9.42$56,520.00View SEC Filing  
10/16/2015Edward J. StewartinsiderSell1,000$10.00$10,000.00View SEC Filing  
10/2/2015Edward J. StewartinsiderSell5,000$8.20$41,000.00View SEC Filing  
9/1/2015Edward J. StewartinsiderSell6,000$9.88$59,280.00View SEC Filing  
8/21/2015Michael E PorterDirectorBuy5,000$9.76$48,800.00View SEC Filing  
8/17/2015Edward J. StewartinsiderSell6,000$10.49$62,940.00View SEC Filing  
8/14/2015Michael E PorterDirectorBuy13,000$10.54$137,020.00View SEC Filing  
7/20/2015Ulrik B NielsenDirectorSell20,000$10.71$214,200.00View SEC Filing  
7/15/2015Edward J StewartInsiderSell6,000$11.84$71,040.00View SEC Filing  
7/15/2015William A SullivanCFOSell15,000$11.85$177,750.00View SEC Filing  
6/19/2015Ulrik B NielsenDirectorSell40,000$12.02$480,800.00View SEC Filing  
6/18/2015Edward J StewartInsiderSell2,000$12.00$24,000.00View SEC Filing  
6/15/2015Edward J StewartInsiderSell6,000$10.67$64,020.00View SEC Filing  
6/15/2015William A SullivanCFOSell15,000$10.65$159,750.00View SEC Filing  
5/19/2015Ulrik B NielsenDirectorSell40,000$13.04$521,600.00View SEC Filing  
5/13/2015Michael E PorterDirectorBuy8,284$11.79$97,668.36View SEC Filing  
4/20/2015Ulrik B NielsenDirectorSell40,000$12.88$515,200.00View SEC Filing  
4/15/2015Edward J StewartSVPSell8,000$12.79$102,320.00View SEC Filing  
4/15/2015William A SullivanCFOSell15,000$12.87$193,050.00View SEC Filing  
4/13/2015Gordon J FehrDirectorSell20,000$13.00$260,000.00View SEC Filing  
3/24/2015Robert J MulroyCEOSell114,368$11.71$1,339,249.28View SEC Filing  
3/23/2015Robert J MulroyCEOSell10,400$11.69$121,576.00View SEC Filing  
3/20/2015Michael E PorterDirectorBuy5,000$11.77$58,850.00View SEC Filing  
3/19/2015Ulrik B NielsenDirectorSell40,000$11.97$478,800.00View SEC Filing  
3/19/2015William A SullivanCFOSell15,000$11.97$179,550.00View SEC Filing  
3/17/2015Birgit M SchoeberlInsiderSell42,234$12.00$506,808.00View SEC Filing  
3/17/2015Edward J StewartSVPSell8,000$11.95$95,600.00View SEC Filing  
3/17/2015Michael E PorterDirectorBuy1,190$11.77$14,006.30View SEC Filing  
3/16/2015Birgit M SchoeberlInsiderSell20,897$12.00$250,764.00View SEC Filing  
3/16/2015Edward J StewartSVPSell6,000$11.93$71,580.00View SEC Filing  
3/11/2015Michael E PorterDirectorBuy5,000$11.33$56,650.00View SEC Filing  
3/2/2015Michael E PorterDirectorBuy5,000$10.93$54,650.00View SEC Filing  
2/23/2015Ulrik B NielsenDirectorSell20,000$10.91$218,200.00View SEC Filing  
2/20/2015Robert J MulroyCEOSell150,000$10.94$1,641,000.00View SEC Filing  
1/15/2015Edward J StewartSVPSell6,000$11.19$67,140.00View SEC Filing  
12/24/2014William A SullivanCFOSell15,000$10.70$160,500.00View SEC Filing  
12/23/2014Vivian S LeeDirectorBuy20,000$10.23$204,600.00View SEC Filing  
12/18/2014Anthony J SinskeyDirectorSell20,000$10.31$206,200.00View SEC Filing  
12/15/2014Edward J StewartSVPSell6,000$10.63$63,780.00View SEC Filing  
12/8/2014Robert J MulroyCEOSell200,000$9.84$1,968,000.00View SEC Filing  
12/2/2014Michael E PorterDirectorBuy8,000$8.71$69,680.00View SEC Filing  
11/21/2014Michael E PorterDirectorBuy11,909$8.87$105,632.83View SEC Filing  
11/18/2014Edward J StewartSVPSell5,000$8.55$42,750.00View SEC Filing  
11/14/2014Michael E PorterDirectorBuy5,000$8.29$41,450.00View SEC Filing  
11/13/2014Gary L CrockerDirectorBuy14,390$8.47$121,883.30View SEC Filing  
11/12/2014Michael E PorterDirectorBuy40,000$8.37$334,800.00View SEC Filing  
10/23/2014Edward J StewartSVPSell3,000$9.05$27,150.00View SEC Filing  
9/30/2014William A SullivanCFOSell105,282$8.61$906,478.02View SEC Filing  
9/29/2014William A SullivanCFOSell64,404$8.40$540,993.60View SEC Filing  
9/24/2014Edward J StewartSVPSell12,000$8.22$98,640.00View SEC Filing  
6/23/2014Gary L CrockerDirectorBuy36,000$6.84$246,240.00View SEC Filing  
5/20/2014Gary CrockerDirectorBuy4,000$6.69$26,760.00View SEC Filing  
5/19/2014Gary CrockerDirectorBuy9,400$6.68$62,792.00View SEC Filing  
5/16/2014Michael PorterDirectorBuy15,000$6.49$97,350.00View SEC Filing  
5/13/2014Anthony SinskeyDirectorBuy5,000$6.74$33,700.00View SEC Filing  
5/8/2014Michael PorterDirectorBuy10,000$6.59$65,900.00View SEC Filing  
5/7/2014Gary CrockerDirectorBuy4,400$6.77$29,788.00View SEC Filing  
5/6/2014Gary CrockerDirectorBuy17,500$6.89$120,575.00View SEC Filing  
5/5/2014Michael PorterDirectorBuy15,000$6.41$96,150.00View SEC Filing  
5/5/2014Robert MulroyCEOBuy5,000$6.31$31,550.00View SEC Filing  
12/17/2013Michael PorterDirectorBuy25,000$4.75$118,750.00View SEC Filing  
12/12/2013William McclementsSVPBuy4,000$4.26$17,040.00View SEC Filing  
12/10/2013Michael PorterDirectorBuy18,000$4.38$78,840.00View SEC Filing  
12/6/2013James QuigleyDirectorBuy39,000$4.70$183,300.00View SEC Filing  
12/4/2013Robert MulroyCEOBuy33,100$4.42$146,302.00View SEC Filing  
12/3/2013Sarah NashDirectorBuy47,500$4.17$198,075.00View SEC Filing  
12/2/2013William McclementsSVPBuy2,000$4.06$8,120.00View SEC Filing  
11/29/2013Anthony SinskeyDirectorBuy3,800$3.92$14,896.00View SEC Filing  
11/27/2013Gary CrockerDirectorBuy207,000$3.72$770,040.00View SEC Filing  
12/14/2012John MendelsohnDirectorBuy5,000$6.63$33,150.00View SEC Filing  
12/13/2012Gary L CrockerDirectorBuy36,500$6.77$247,105.00View SEC Filing  
12/10/2012Michael E PorterDirectorBuy10,000$6.08$60,800.00View SEC Filing  
9/14/2012Gary L CrockerDirectorBuy64,800$8.33$539,784.00View SEC Filing  
8/24/2012James H QuigleyDirectorBuy12,500$7.55$94,375.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Merrimack Pharmaceuticals (NASDAQ:MACK)
News IconBiotech Stocks Worth a Closer Look: Intrexon Corporation (NYSE:XON), Merrimack Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:MACK) - August 25 at 11:09 AM
News IconActive biotech company shares in the news: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Amicus Therapeutics ... - The Voice Registrar (NASDAQ:MACK) - August 25 at 11:09 AM
News IconHot Biotech Stocks Recap: Inovio Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:MACK) - August 24 at 5:54 PM
News IconStock to Watch: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK ... - Newburg Press (NASDAQ:MACK) - August 22 at 6:03 PM logoETF’s with exposure to Merrimack Pharmaceuticals, Inc. : August 22, 2016 (NASDAQ:MACK) - August 22 at 6:03 PM logoWill Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Hit $16 Price Target? - Investor Newswire (NASDAQ:MACK) - August 20 at 5:50 PM logoExpect Merrimack Pharma Shares To Be Range-Bound For The Near Term (NASDAQ:MACK) - August 20 at 10:10 AM
News IconTime To Put On The Watch List? - Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Amicus Therapeutics, Inc ... - The Voice Registrar (NASDAQ:MACK) - August 19 at 6:00 PM
News IconNews review of 2 biotech stocks: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Pacific Biosciences of California ... - The Voice Registrar (NASDAQ:MACK) - August 19 at 6:00 PM
News IconMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Earnings Preview: Should Investors Be Nervous? - The Voice Registrar (NASDAQ:MACK) - August 17 at 9:07 AM logoMERRIMACK PHARMACEUTICALS INC Financials (NASDAQ:MACK) - August 12 at 6:08 PM logoMerrimack Pharmaceuticals, Inc. :MACK-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:MACK) - August 10 at 6:25 PM logoETF’s with exposure to Merrimack Pharmaceuticals, Inc. : August 9, 2016 (NASDAQ:MACK) - August 9 at 6:17 PM
News IconMGT Capital Investments Inc. (NYSEMKT:MGT) Is Poised For Industry Leadership (NASDAQ:MACK) - August 9 at 9:10 AM logoMerrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MACK-US : August 8, 2016 (NASDAQ:MACK) - August 8 at 10:45 AM logoMerrimack (MACK) Q2 Loss Wider than Expected, Sales Top (NASDAQ:MACK) - August 5 at 6:12 PM logoEdited Transcript of MACK earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:MACK) - August 5 at 6:12 PM logoMerrimack Reports Second Quarter 2016 Financial Results (NASDAQ:MACK) - August 4 at 6:25 PM logoEarnings Reaction History: Merrimack Pharmaceuticals Inc, 40.0% Follow-Through Indicator, 8.8% Sensitive (NASDAQ:MACK) - August 4 at 6:25 PM logoMerrimack Pharmaceuticals Inc.: Merrimack Reports Second Quarter 2016 Financial Results (NASDAQ:MACK) - August 4 at 6:25 PM logoMerrimack reports 2Q loss (NASDAQ:MACK) - August 4 at 6:25 PM logoQ2 2016 Merrimack Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:MACK) - August 4 at 9:11 AM logoNew Broker Ratings For Merrimack Pharmaceuticals, Inc. (MACK) - FTSE News (NASDAQ:MACK) - August 3 at 9:21 AM logoStock Analyst Opinions On Watch List: Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Inc. (NASDAQ ... - Review Fortune (NASDAQ:MACK) - August 2 at 10:52 AM logoStocks in Review: Merrimack Pharmaceuticals, Inc. (MACK), Invesco Ltd. (IVZ), Sanchez Energy Corporation (SN) - iStreetWire (NASDAQ:MACK) - August 2 at 10:52 AM
News IconBiotechnology Stocks Under Consideration: Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Mast Therapeutics Inc ... - Post Registrar (NASDAQ:MACK) - August 2 at 10:52 AM logoMerrimack (MACK): Can the Stock Surprise in Q2 Earnings? (NASDAQ:MACK) - August 1 at 5:53 PM logoMerrimack Pharmaceuticals: Trade On Breakout (NASDAQ:MACK) - August 1 at 10:46 AM logoMerrimack Pharmaceuticals: Trade On Breakout - (NASDAQ:MACK) - July 31 at 5:41 PM logoNajarian Stake Brings Out Merrimack Pharmaceuticals Inc (MACK ... - Schaeffers Research (blog) (NASDAQ:MACK) - July 31 at 10:14 AM logoNajarian Stake Brings Out Merrimack Pharmaceuticals Inc (MACK) Option Bulls (NASDAQ:MACK) - July 30 at 8:55 AM logoCan Shares Of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Hit $16? - Investor Newswire (NASDAQ:MACK) - July 29 at 6:12 PM logoETF’s with exposure to Merrimack Pharmaceuticals, Inc. : July 29, 2016 (NASDAQ:MACK) - July 29 at 12:47 PM logoAnalysts Spotlight: Baxter International Inc. (NYSE:BAX) , Merrimack ... - Street Updates (NASDAQ:MACK) - July 29 at 9:04 AM logoNew Broker Ratings For Merrimack Pharmaceuticals, Inc. (MACK ... - FTSE News (NASDAQ:MACK) - July 28 at 9:12 AM logoLatest Analysts Tips Update: Baxter International Inc. (NYSE:BAX) , Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - Street Updates (NASDAQ:MACK) - July 28 at 9:12 AM logoCurrent Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) PT ... - Review Fortune (NASDAQ:MACK) - July 28 at 9:12 AM logoStocks Worth Mentioning Ratings-Wise: Tiffany & Co. (NYSE:TIF), Merrimack Pharmaceuticals Inc (NASDAQ:MACK) - Review Fortune (NASDAQ:MACK) - July 26 at 6:21 PM logoStock Update (NASDAQ:MACK): Merrimack Pharmaceuticals Inc Announces ONIVYDE® Regimen Receives Positive ... - Smarter Analyst (NASDAQ:MACK) - July 26 at 6:21 PM logoMerrimack Pharmaceuticals (MACK) Up on EU Nod (NASDAQ:MACK) - July 26 at 9:09 AM logoMerrimack's (MACK) ONIVYDE Receives Positive CHMP Opinion (NASDAQ:MACK) - July 26 at 9:09 AM
News IconIntraday Active Biotech Stocks News: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Merrimack Pharmaceuticals ... - The Voice Registrar (NASDAQ:MACK) - July 25 at 6:12 PM
News IconStocks Logging Active Run: Wal-Mart Stores (NYSE:WMT), Merrimack Pharmaceuticals (NASDAQ:MACK), G-III Apparel ... - Seneca Globe (NASDAQ:MACK) - July 25 at 10:35 AM logoStocks inside Analysts Spotlight: Cigna Corporation (NYSE:CI) , Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - Street Updates (NASDAQ:MACK) - July 25 at 10:35 AM
News IconHC Stocks Summary: Centene Corp (NYSE:CNC) Merrimack Pharmaceuticals Inc (NASDAQ:MACK) - share market updates (press release) (NASDAQ:MACK) - July 25 at 10:35 AM logoMerrimack Announces ONIVYDE® Regimen Receives Positive CHMP Opinion in European Union (NASDAQ:MACK) - July 25 at 2:28 AM logoWhich way Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insiders are heading - Review Fortune (NASDAQ:MACK) - July 23 at 5:43 PM logoMomentum Stocks in Focus: Xilinx Inc. (XLNX) Merrimack Pharmaceuticals, Inc. (MACK) HCA Holdings, Inc. (HCA) - iStreetWire (NASDAQ:MACK) - July 21 at 6:17 PM
News IconMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:MACK) - July 21 at 6:17 PM
News IconPrice Target Highlight: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - News Oracle (NASDAQ:MACK) - July 21 at 6:17 PM


Merrimack Pharmaceuticals (NASDAQ:MACK) Chart for Friday, August, 26, 2016

Last Updated on 8/26/2016 by Staff